7 results
To demonstrate superiority with regard to Progression Free Survival based on an Independent Review Committeeassessment of avelumab versus platinum-based doublet in NSCLC subjects with PD-L1+
Primary Objective: to evaluate clinical efficacy of domatinostat in combination with avelumab in treatment-naïve metastatic or distally recurrent MCC patients as determined by the Objective Response Rate (ORR) according to Response Evaluation…
• Determine the maximum tolerated dose (MTD) and/or recommended dose (RD) for further evaluation of XL092 when administered alone and in combination with ICIs to subjects with advanced solid tumors• Evaluate preliminary efficacy of XL092 when…
The aim is to evaluate whether the use of eRFA prior to stenting prolongs stent patency in patients with biliary obstruction due to inoperable perihilar cholangocarcinoma.
Primary objective: • To assess the pharmacokinetics of DOR in patients prior to and after BSSecondary objectives: • To assess the safety of DOR in patients prior to and after undergoing BS• To assess the viral response to DOR in patients prior to…
Objectives:Primary Objective: to investigate the anti-tumor efficacy of domatinostat in combination with avelumab in advanced unresectable/metastatic MCC patients progressing on anti-PD-(L)1 antibody monotherapy.Secondary Objectives: to investigate…
It is hypothesized that eRFA leads to increased stent patency, fewer re-interventions, fewer (permanent) external drains, and consequently increased quality of life. The primary aim of the proposed pilot study is to evaluate whether eRFA is feasible…